

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

**MEDICAL
INTELLIGENCE
UNIT 24**

Peptide-Based Cancer Vaccines

W. Martin Kast, Ph.D.

Professor of Microbiology, Immunology and Pharmacology
Director, Cancer Immunology Program
Cardinal Bernardin Cancer Center
Loyola University Chicago
Maywood, Illinois, U.S.A.

LANDES BIOSCIENCE
GEORGETOWN, TEXAS
U.S.A.

EUREKAH.COM
AUSTIN, TEXAS
U.S.A.

PEPTIDE-BASED CANCER VACCINES

Medical Intelligence Unit

Eurekah.com
Landes Bioscience

Copyright ©2000 Eurekah.com
All rights reserved.

No part of this book may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

Printed in the U.S.A.

Please address all inquiries to the Publishers:
Eurekah.com / Landes Bioscience, 810 South Church Street
Georgetown, Texas, U.S.A. 78626
Phone: 512/ 863 7762; FAX: 512/ 863 0081
www.eurekah.com
www.landesbioscience.com

ISBN: 1-58706-026-4

While the authors, editors and publisher believe that drug selection and dosage and the specifications and usage of equipment and devices, as set forth in this book, are in accord with current recommendations and practice at the time of publication, they make no warranty, expressed or implied, with respect to material described in this book. In view of the ongoing research, equipment development, changes in governmental regulations and the rapid accumulation of information relating to the biomedical sciences, the reader is urged to carefully review and evaluate the information provided herein.

Library of Congress Cataloging-in-Publication Data

Peptide-based cancer vaccines/(edited by) W. Martin Kast

p. ; cm.--(Medical Intelligence Unit).

Includes bibliographical references and index.

ISBN 1-58706-026-4 (alk. paper)

1. Cancer--Immunotherapy. 2. Vaccines. 3. Peptide drugs. I. Kast W. Martin. II. Series.

(DNLM: 1. Cancer Vaccines. 2. Peptides--therapeutic use. QZ 267 P4235
2000) RC271.L45 P462000

616.99'406--dc21

1. Identifi
from Ti
of Imm
Esteban
Introd
Identi
Im
In Vit
fro
Concl

2. Mutant
and Fu
as Targ
V. Eller
Mich
Leon
and J
Introc
Ras ...
p53 ..
Fusio
Ch
Sumn

3. p53: A
Michel
W. A
Intro
p53 a
Wild
Immu
Muta
Wild
Ackn

4. Critica
of Epi
Gregor
Lau
Diar
Rem
Intro
Pepti
Denc
DNA
Reco
Conc

CHAPTER 1

Identification and Selection of T-Cell Epitopes Derived from Tumor-Associated Antigens for the Development of Immunotherapy for Cancer

Esteban Celis

Because the immune system has the capacity to recognize and in many cases destroy tumor cells, significant efforts are being devoted to the development of immune-based therapies for cancer. Both cytotoxic T lymphocytes (CTL) and helper T lymphocytes (HTL) have been shown to react with antigens expressed by tumor cells and as a result, establish protective and therapeutic effects. Since CTL and HTL recognize antigens in the form of peptide complexes with major histocompatibility complex (MHC) surface molecules (HLA in humans), it is necessary to identify the nature of tumor-derived peptides that can elicit T-cell responses capable of inhibiting tumor-cell growth. The overall objective of our work is to identify peptides derived from sequences of several known tumor-associated antigens (TAA) that are capable of stimulating CTL and HTL against tumor cells. The amino acid sequences of TAA are screened for the presence of peptides containing MHC binding motifs. Corresponding peptides are then synthesized and tested for their capacity to elicit in vitro T-cell responses to tumor cells and corresponding TAA as a final proof that they truly represent T-cell epitopes. As a consequence of these studies, the identified tumor-reactive T-cell epitopes can be developed into therapeutic compounds to treat commonly found epithelial cancers (breast, gastrointestinal and lung). The remaining challenges are how to select the most appropriate mode of vaccination and how to evaluate the effectiveness of immunotherapy in the cancer setting.

Introduction

The incidence of many types of tumors including breast, prostatic, colorectal and lung carcinomas continues to rise in the majority of developed and underdeveloped countries. Most importantly, there is a desperate need to develop non-toxic therapies to eliminate disease, prevent tumor recurrences and inhibit metastatic dissemination, all which should prolong survival while maintaining a good quality of life. Immunotherapy must be considered as the best alternative to accomplish this goal. The purpose of this Chapter is to describe our group's approach to develop effective immune-based therapies for the treatment of commonly found types of cancer. Our belief is that T-lymphocytes are the most efficient constituents of the immune system that are capable of limiting tumor cell growth. Based on this bias, the goal of our studies

has been to determine the best approach to induce strong and effective anti-tumor-specific T-cell responses as a means of developing epitope-based therapeutic vaccines for cancer.

T-Cells and Cancer

It is well accepted that the immune system has the ability to recognize and eliminate many types of tumors. As a consequence, significant efforts have been devoted in the last 20 years to the development of immune-based therapies for cancer. Cytotoxic T lymphocytes (CTL) and helper T lymphocytes (HTL) have been shown to react with antigens expressed by tumor cells and in many circumstances T-cell reactivity against tumor-derived antigens results in the induction of protective and therapeutic anti-tumor effects. While CTL can directly kill the tumor cells they recognize, antigen-specific HTL will amplify CTL responses and may also exhibit anti-tumor responses by producing lymphokines that directly inhibit tumor-cell growth. In several murine tumor model systems it has been clearly demonstrated that T-cells, and in particular CTL, are capable of eliminating established tumors. Adoptive transfer of tumor-reactive CTL,^{1,2,5,6} active immunization using dendritic cells (DC) pulsed with CTL epitopes^{7,8} or the use of strong co-stimulatory signals which increase CTL responses have all been reported as successful means of eliminating relatively large established tumors.

In humans, adoptive transfer of tumor-reactive T-cells (sometimes in combination with cytokines), has resulted in objective anti-tumor responses and in many cases in total tumor eradication.^{5,6} Although these results have been most encouraging in limited types of tumors such as melanoma, renal cell carcinoma and B-cell lymphomas, positive responses are not observed in all patients. Furthermore, this mode of therapy has not been applicable to the most frequently encountered malignancies such as breast, lung, prostate and gastrointestinal carcinomas. With respect to active immunization, impressive therapeutic responses have been reported in melanoma patients immunized with peptides corresponding to CTL epitopes that were administered in combination with GM-CSF, IL-2 or pulsed onto DC.¹¹⁻¹⁴ However, as with adoptive therapy, not all patients responded favorably to this mode of immunotherapy and the applicability of this approach to other tumor types is limited because the appropriate CTL epitopes are yet to be defined.

The most likely explanation for these inconsistent results is that tumor cells vary significantly with respect to their antigenic composition and hence melanomas, renal carcinomas and B-cell lymphomas have been considered as "immuno-responsive", while most other tumors are regarded as "poorly immunogenic". Another possible cause for the variability observed in responses to T-cell adoptive therapy within the same tumor type is that the content of "antigen-specific" effector T-cells that are present in the cell product infused into the patients is usually not equivalent from patient to patient. Thus, the identification of relevant TAA and corresponding epitopes for tumor-reactive T-cells will certainly broaden the type of tumors suitable for immunotherapy and should increase the efficacy of therapeutic vaccines or adoptive therapy approaches by facilitating the induction of antigen-specific effector cells.

Although CTL are considered to be the main effector of anti-tumor immune responses, HTL play a pivotal role in enhancing tumor-reactive effector immune responses. Furthermore, HTL may also participate in the establishment of long-term immunity, which is essential for the prevention of tumor recurrences. It has been clearly demonstrated that restoration of long-term immunity by adoptive transfer of CTL requires the presence of antigen-specific HTL.^{6,15,16} Thus, a T-cell mediated immunotherapy approach for tumors must include, in addition to the induction of CTL, the concurrent stimulation of TAA-specific T helper cells that will not only potentiate the therapeutic effect, but will also provide long-lasting immunological memory.

Antigen Recognition

T cells recognize and kill target cells by interacting with major histocompatibility complex (MHC) molecules on the cell surface. The T cell receptor (TCR) of CTL bind to the MHC-peptide complex (APC) formed by peptide (TAA) and major histocompatibility complex (MHC) molecules that are recognized by CTL. CTL interact with the MHC-peptide complex valently with polymorphic CD4 surface marker and MHC class II molecules, which are recognized by CTL. CTL are also recognized by monocytes/macrophages.

Many normal and tumor-associated proteins derived from germline and somatic cells bind binding peptides which are recognized by CTL. After TCR engagement by the MHC-peptide complex and kill target cells expressing the MHC-peptide complex. CTL immune response is mediated by presenting the antigen on the MHC-peptide complex.

Strategies to Identify

Some of the changes in the immune system that are immunogenic; 2) abnormal overexpression of oncogenes; 3) overexpression of oncogenes.

Over several decades, "tumor markers" have been identified. These antigens were first identified in the late 19th century when immunity was unclear. However, these tumor markers are not always expressed by CTL and HTL.

Two new approaches have made it possible to identify antigens for T lymphocytes. Both approaches have been pioneered by tumor bearing patients and their collaborators. In murine model systems, a family of genes (designated as MHC class I) proportion of breast, lung, and colon of the testes) designated as CTL were defined as 9 and 10. CTL with class I MHC molecules (tyrosinase, gp75, p15, BA) have been identified by several methods. CTL have been demonstrated to be expressed in melanoma, and that immune tolerance is not necessarily always correlated with CTL and HTL.

ing and effective anti-tumor-specific T-erapeutic vaccines for cancer.

ility to recognize and eliminate many e been devoted in the last 20 years to Cytotoxic T lymphocytes (CTL) and ith antigens expressed by tumor cells or-derived antigens results in the in- While CTL can directly kill the tu- lify CTL responses and may also ex- at directly inhibit tumor-cell growth. ly demonstrated that T-cells, and in umors. Adoptive transfer of tumor- cells (DC) pulsed with CTL epitopes rease CTL responses have all been e established tumors. lls (sometimes in combination with es and in may cases in total tumor ouraging in limited types of tumors omas, positive responses are not ob- has not been applicable to the most , prostate and gastrointestinal carci- therapeutic responses have been re- sponding to CTL epitopes that r pulsed onto DC.¹¹⁻¹⁴ However, as ly to this mode of immunotherapy s is limited because the appropriate

ults is that tumor cells vary signifi- e melanomas, renal carcinomas and nsive", while most other tumors are e for the variability observed in re- type is that the content of "antigen- infused into the patients is usually cation of relevant TAA and corre- roaden the type of tumors suitable peutic vaccines or adoptive therapy effector cells.

of anti-tumor immune responses, r immune responses. Furthermore, n immunity, which is essential for onstrated that restoration of long- nce of antigen-specific HTL.^{6,15,16} rs must include, in addition to the fic T helper cells that will not only lasting immunological memory.

Antigen Recognition by T-Cells

T cells recognize antigen as small peptides bound to cell surface molecules encoded by the major histocompatibility gene complex (MHC). CTL are characterized by expression of CD8 cell surface molecules and by their capacity to induce lysis of the target cells they react with via the perforin/granzyme and/or the Fas/Fas-L pathways.^{17,18} The T-cell receptors for antigen (TCR) of CTL bind to a molecular complex on the surface of the antigen-presenting cells (APC) formed by peptide epitopes usually derived from viral or tumor-associated antigens (TAA) and major histocompatibility gene complex (MHC) class I molecules. The peptides that are recognized by CTL are usually fragments 8-10 residues long that associate non-covalently with polymorphic class I MHC molecules.¹⁹ On the other hand, HTL express the CD4 surface marker and recognize slightly larger peptides (12-20 residues) in the context of MHC class II molecules, which are only expressed in specific types APC such as B-lymphocytes, monocytes/macrophages and DC.²⁰

Many normal and abnormal (e.g., oncogene products) cellular components as well as proteins derived from genes of foreign intracellular microorganisms are processed into MHC-binding peptides which are transported to the APC surface for presentation to the TCR.^{19,20} After TCR engagement by appropriate MHC-peptide complexes, CTL have the ability to bind and kill target cells expressing foreign (infectious) or TAA. On the other hand, as a result of MHC-peptide recognition by HTL, these cells produce lymphokines that enhance and amplify CTL immune responses, or in some cases, HTL may also induce the lysis of the cell presenting the antigen or bystander cells via cytolytic mechanisms such as TNF and Fas ligand.

Strategies to Identify TAA and Selection of T-Cell Epitopes

Some of the changes that occur during cell transformation can produce MHC-binding peptides that are immunogenic for CTL or HTL. These TAA include: 1) oncogenic viral proteins; 2) abnormal overexpression of fetal or tissue specific proteins; and 3) mutated or overexpressed oncogene or tumor suppressor gene products.²¹⁻²⁶

Over several decades various TAA such as CEA, PSA, HER2 and p53, which serve as "tumor markers" have been identified and biochemically characterized.^{21,23-28} Because many of these antigens were first identified serologically or genetically, their relevance to CTL and HTL immunity was unclear. However, at the present time, there is sufficient evidence indicating that these tumor markers are capable of producing MHC-binding peptides that are recognized by CTL and HTL.

Two new approaches based on advanced molecular biology and immunology techniques has made it possible to identify several additional cellular products that can function as TAA for T lymphocytes. Both approaches rely on the availability of tumor-reactive CTL obtained from tumor bearing patients to screen gene libraries or peptide fraction isolates. T. Boon and collaborators pioneered the identification of TAA encoding genes of non-viral origin, originally in murine model systems and later in human melanomas.²² This approach was used to identify a family of genes expressed predominantly in human melanomas (but also in a small proportion of breast, lung and colon carcinomas) and not in most normal tissues (with exception of the testes) designated MAGE.²⁹ Several CTL epitopes recognized by a melanoma patient's CTL were defined as 9 amino acid peptides which were presented to the TCR in association with class I MHC molecules. Various additional TAA (MART1/Melan-A; pmel-17/gp100, tyrosinase, gp75, p15, BAGE, GAGE, and others), also expressed mainly in melanomas, have been identified by several groups using the same methodology.^{4,34-45} These proteins in addition to being expressed in melanomas, are also found in normal melanocytes. These observations demonstrate that under some circumstances TAA can be derived from normal cell constituents, and that immune tolerance to "self-antigens" at the CTL, and possibly at the HTL level is not necessarily always complete.⁴⁶ Another approach to identify TAA is to directly sequence

MHC-binding peptides that are eluted and purified from tumor cells.⁴⁷⁻⁴⁹ This technique requires large numbers of tumor cells from which MHC molecules can be purified together with accurate and sensitive methods to characterize the eluted peptides and as in the previous method, TAA-reactive CTL, usually isolated from tumor patients are required to identify the active peptide fractions before they are sequenced by tandem-mass spectrography.

Identification of T-Cell Epitopes for Tumor Cells Using Reverse Immunology

MHC-Binding Peptides as Potential T-Cell Epitopes

We have developed a completely different strategy to identify peptide epitopes for CTL which can be extended to HTL. These T-cell epitopes are derived from known TAA and the approach does not require the use of patient's tumor-reactive T-cells (which have been very difficult to isolate for tumors other than melanoma and renal-cell Ca) to screen DNA libraries or peptide fractions. This method involves three critical steps: i) identification of defined MHC binding motifs for the major HLA alleles; ii) selection of peptide sequences from putative or known TAA that contain these motifs and measurement of their capacity to bind to purified MHC molecules; and iii) determination of which MHC-binding peptides can elicit in vitro CTL that are capable of killing tumor cells that express the TAA.⁵⁰⁻⁵³

An important factor to consider in the identification of TAA is whether a peptide can bind to a specific MHC allele since MHC binding is a prerequisite for immunogenicity. Peptide binding to an individual MHC molecule depends on the specific sequence of the peptide.^{19,54} Analysis of the sequence patterns of peptides that bind to MHC molecules in humans and mice has revealed the presence of primary and secondary anchor residues. MHC molecules are extremely polymorphic, and theoretically each allelic type will bind different sets of peptides (different alleles of the MHC tend to vary in those residues that form part of the peptide binding pockets). The MHC binding motifs for the most frequently found class I alleles (HLA-A1, -A2, -A3, -A11, -A24, -B7) as well as those for several major class II molecules (DRB*0101, -DRB*0301, DRB*0401 and DRB*0701) have been reported.⁵⁴⁻⁵⁹ By identifying sets of tumor-associated peptides that bear these motifs and that bind to these the various HLA molecules, one could offer coverage to the majority of the human population (>80%) for developing T-cell epitope-based immunotherapy for tumors.

Once the selected TAA have been screened for sequences that contain MHC binding motifs, synthetic peptides representing these sequences can be synthesized and tested for their capacity to bind purified HLA molecules. Numerous quantitative peptide MHC binding assays have been developed which allow to screen a large number of motif-containing peptides from TAA and determine their binding affinity to several different HLA class I and II alleles. The results presented in Figure 1.1 illustrate an example of a quantitative binding assay of peptides derived from the MAGE antigens to HLA-A1 molecules.⁵¹

The last and probably most difficult step in the T-cell epitope identification process is to determine whether the peptides that have been identified as MHC binders are capable of inducing anti-tumor CTL or HTL responses. Primary T-cell immunization using synthetic peptides can be done in vitro using human peripheral blood mononuclear cells (PBMC) from appropriate HLA-typed individuals. In the following section we will present several examples where our group has been successful using this strategy in identifying numerous CTL epitopes for melanoma and solid epithelial tumors. The same approach should be applicable for the identification of tumor-reactive HTL.

% Inhibition

Fig. 1.1. HLA-A1 bi in a dose titration fo to purified HLA-A1 (■), MAGE-2 pept calculate the 50% i binding affinity of th C et al. Proc Natl A

In Vitro Imm from MAGE

The identific cient to guarantee onstrate that the i corresponding pep it is possible to im strate that the resp antigen. In humar the responses of T the T-cell precurs limitations that ir specific T-cell line in more detail belo epitopes whereas cover both domin

In view of th utilizes peptide-pi (PBMC) of norm onstrate the feasib munization with p sented in Figure 1 antigen (Fig. 1.1)

Subsequently the use of tissue c were able to gener

om tumor cells.⁴⁷⁻⁴⁹ This technique
molecules can be purified together
luted peptides and as in the previous
patients are required to identify the
lem-mass spectrography.

r Cells Using Reverse

topes

o identify peptide epitopes for CTL
derived from known TAA and the
ctive T-cells (which have been very
nal-cell Ca) to screen DNA libraries
s: i) identification of defined MHC
peptide sequences from putative or
f their capacity to bind to purified
binding peptides can elicit in vitro
TAA.⁵⁰⁻⁵³

FTAA is whether a peptide can bind
isite for immunogenicity. Peptide
ecific sequence of the peptide.^{19,54}

MHC molecules in humans and
chor residues. MHC molecules are
will bind different sets of peptides
ues that form part of the peptide
quently found class I alleles (HLA-
ior class II molecules (DRB*0101,
ted.⁵⁴⁻⁵⁹ By identifying sets of tu-
rd to these the various HLA mol-
n population (>80%) for develop-

nces that contain MHC binding
be synthesized and tested for their
itative peptide MHC binding as-
ber of motif-containing peptides
fferent HLA class I and II alleles.
f a quantitative binding assay of
xules.⁵¹

pitope identification process is to
MHC binders are capable of in-
munization using synthetic pep-
nonuclear cells (PBMC) from
we will present several examples
nifying numerous CTL epitopes
ch should be applicable for the




Fig. 1.1. HLA-A1 binding of synthetic peptides from MAGE-1, -2 and -3. The MAGE peptides were tested in a dose titration for the inhibition of the binding of the radiolabeled standard peptide ¹²⁵I-YLEPAIAKY to purified HLA-A1 molecules as described. Peptides tested were: (●), MAGE-1 peptide EADPTGHSY; (■), MAGE-2 peptide EVVPISHLY; (○), MAGE-3 peptide EVDPIGHLY. Dotted lines are used to calculate the 50% inhibitory concentration (IC₅₀) for each peptide, which inversely correlates with the binding affinity of the peptide to the HLA molecule. Reprinted with permission from: Celis E, Tsai V, Crimi C et al. Proc Natl Acad Sci (USA) 1994; 91:2105-2109. ©1994 National Academy of Sciences, USA.

In Vitro Immunization of T-Cells Using MHC-Binding Peptides from MAGE Antigens

The identification of MHC-binding peptides from known antigen sequences is not sufficient to guarantee that these peptides truly represent to T-cell epitopes. It is necessary to demonstrate that the T-cells can recognize cells that naturally process the antigen and present the corresponding peptide to the TCR as an MHC/peptide complex. In animals (mostly in mice) it is possible to immunize with peptides corresponding to putative T-cell epitopes and demonstrate that the responding T-cells can kill or proliferate to APC that process the corresponding antigen. In humans this type of approach is not feasible and one is limited to either evaluating the responses of T-cells isolated from patients or performing in vitro primary immunization of the T-cell precursors. As mentioned in previous sections, the use of patient-derived T-cell has limitations that in many types of cancer, especially the ones we wish to study here, antigen-specific T-cell lines/clones have been difficult to establish. Furthermore, as will be mentioned in more detail below, T-cells from patients will respond primarily to classical "immunodominant" epitopes whereas (in vitro) immunization studies using defined peptide epitopes should uncover both dominant and subdominant T-cell epitopes.⁶²

In view of the above, we have developed an in vitro CTL immunization procedure that utilizes peptide-pulsed APC and CTL precursors from peripheral blood mononuclear cells (PBMC) of normal individuals.^{61,63} Using this procedure our laboratory was the first to demonstrate the feasibility of inducing tumor-reactive CTL in normal individuals by in vitro immunization with peptide pulsed activated autologous epitopes B-cells as APC. The results presented in Figure 1.2 show that the HLA-A1-binding peptide that we identified from the MAGE-3 antigen (Fig. 1.1) was efficient in inducing peptide and tumor (melanoma) reactive CTL.

Subsequently, the technique of in vitro immunization of CTL was greatly improved by the use of tissue culture generated DC^{64,65} that are used as professional APC. With DC we were able to generate primary CTL to a hepatitis B virus epitope in close to one 100% (1212)




Fig. 1.2. Antigen-specificity and MHC-restriction analysis of MAGE-3 reactive CTL. Cytotoxic responses using peptide-loaded target cells and melanoma tumors: (▲), Steinlin (HLA-A1* homozygous, Epstein-Barr Virus-transformed lymphoblastoid cell line (EBV-LCL), pulsed with MAGE-3 peptide EVDPIGHLY; (●), Steinlin cells (EBV-LCL) pulsed with MAGE-1 peptide EADPTGHSY; (○), Steinlin cells with no peptide; (▼), 397mel (HLA-A1*, MAGE-3*); (◆), 938mel (HLA-A1*, MAGE-3*); (◇), 888mel (HLA-A1* MAGE-3*); (▽), 526mel (HLA-A2*, MAGE-3*). Reprinted with permission from: Celis E, Tsai V, Crimi C et al. *Proc Natl Acad Sci (USA)* 1994; 91:2105-2109. ©1994 National Academy Sciences, USA.

normal individuals. Moreover, the majority of the peptide-reactive CTL (>80%) were also capable of recognizing target cells that naturally process the hepatitis B virus epitope.⁶¹

Using the newly optimized DC immunization protocol, we proceeded to identify additional MAGE-specific CTL epitopes, but focusing on HLA-A2, one of the most frequently found MHC alleles in humans. In addition, we wished to determine whether MAGE-2 and MAGE-3-reactive CTL could recognize and kill other tumors besides melanomas, which may express these TAA. The rationale for this experiment is based on the published reports that approximately 20-60% of breast, colon and higher numbers of gastric carcinomas express the MAGE antigens.⁶⁶⁻⁶⁸ Although numerous reports by several groups have demonstrated that MAGE-specific CTL were effective in killing MAGE⁺ melanoma tumors,^{30-33,52,69} no one had evaluated if these CTL could also recognize and kill MAGE⁺ tumors of other type. Using peptide-pulsed DC, we tested the capacity of two HLA-A2-binding peptides from MAGE to induce tumor-reactive CTL by in vitro immunization of T-cells, and to determine whether these effector cells were capable of recognizing epithelial (non-melanoma) tumors expressing MAGE and HLA-A2 molecules. The results in Figure 1.3 clearly demonstrate that MAGE-2




Fig. 1.3. Recognition of 166 (YLQLVFGIEV) s. (B) were prepared from Both clones were teste homozygous, EBV-LC tide; △, 624mel (mela-3*); ◇, SW403 (colon 888mel (melanoma, H S, Tsai V et al. Human nogenetics, 1998 Elsev


and MAGE-3 speci efficient in killing N

In collaboratio additional new MA most common MH A24-binding peptid express the MAGE a MAGE antigens ma relatively low freque must be considered

In Vitro Immun Peptides from E₁

Epithelial solc most common type is no knowledge of a could be developed utilize several TAA t treat epithelial-deriv HER2 and CEA, b following we descril

A significant p produce a proto-onc



active CTL. Cytotoxic responses HLA-A1* homozygous, Epstein-MAGE-3 peptide EVDPIGHLY; HSY; (O), Steinlin cells with no MAGE-3*); (◇), 888mel (HLA-ermission from: Celis E, Tsai V, ational Academy Sciences, USA.

tive CTL (>80%) were also itis B virus epitope.⁶¹

proceeded to identify addi-one of the most frequently nine whether MAGE-2 and ides melanomas, which may he published reports that istic carcinomas express the ps have demonstrated that umors,^{30-33,52,69} no one had umors of other type. Using ng peptides from MAGE to and to determine whether lanoma) tumors expressing demonstrate that MAGE-2




Fig. 1.3. Recognition of various tumor types by a MAGE-2 and -3 specific CTL clones. A MAGE-2 p157-166 (YLQLVFGIEV) specific CTL clone (A) and a MAGE-3 p112-120 (KVAELVHFL) specific CTL clone (B) were prepared from PBMC of a normal HLA-A2 donor using peptide-pulsed autologous DC as APC. Both clones were tested for their lytic activity against the following target cells: ○, .221A2.1 (HLA-A2* homozygous, EBV-LCL) pulsed with the corresponding MAGE peptide; ●, .221A2.1 cells without peptide; △, 624mel (melanoma, HLA-A2*, MAGE-2*/3*); □, KATO-III (gastric Ca, HLA-A2*, MAGE-2*/-3*); ◇, SW403 (colon Ca, HLA-A2*, MAGE-2*/3*); ■, WiDr (colon Ca, HLA-A2*, MAGE-2*/-3*); ▲, 888mel (melanoma, HLA-A2*, MAGE-2*/-3*). Reprinted with permission from: Kawashima I, Hudson S, Tsai V et al. Human Immunol 1998; 59:1-14. ©American Society for Histocompatibility and Immunogenetics, 1998 Elsevier Science, Inc.

and MAGE-3 specific CTL that were induced in vitro with peptide-pulsed DC, were very efficient in killing MAGE* melanoma, colon and gastric tumor cell lines.⁷⁰

In collaboration with scientists from Takara Biotechnology, (Japan) we have identified additional new MAGE-specific CTL epitopes that are restricted by HLA-A24 which is the most common MHC class I allele in the Japanese population. The CTL elicited by the HLA-A24-binding peptides were efficient in killing both melanomas and gastric carcinomas that express the MAGE antigens.⁷² These results confirm the prediction that immunotherapy using MAGE antigens may be applicable to tumors other than melanoma. However, because of the relatively low frequency of epithelial tumors that express MAGE, the use of additional TAA must be considered to offer adequate disease coverage.

In Vitro Immunization of Tumor-Reactive CTL Using MHC-Binding Peptides from Epithelial Tumor Markers

Epithelial solid tumors such as lung, gastrointestinal, breast and prostate represent the most common type of malignancies in the human population. Unfortunately, at present there is no knowledge of a single TAA that is expressed in the majority of these types of tumors which could be developed into a therapeutic vaccine. In view of this, it will become necessary to utilize several TAA to provide disease coverage for any immune-based therapeutic approach to treat epithelial-derived tumors. Our laboratory has selected in addition to MAGE, two TAA, HER2 and CEA, both which are found in a significant number of epithelial tumors. In the following we describe our efforts to identify CTL epitopes for these TAA.

A significant proportion (30-60%) of transformed breast epithelial cells overexpress and produce a proto-oncogene product known as HER2 (also known as neu, c-ErbB2, or p185^{HER2}),




Fig. 1. 4. Cytotoxic T lymphocytes induced with HLA-binding peptides from HER2 can kill tumor cells. CTL were induced with the HLA-A2-binding peptide, HER2 p435-443 (ILHNGAYSL) (panel A) or the HLA-A3 binding peptide HER p754-763 (VLRENTSPK) (panel B). Peptide specific CTL were used as effector cells to test for the lysis of following target cell lines: ○, EBV-LCL cells of the appropriate HLA type pulsed with HER p435-443 (in A) or HER p754-763 (in B); ●, EBV-LCL cells without peptide; △, SW403 cells (colon Ca, HLA-A2*/A3*, HER2*); ▲, colon Ca cell line, A2*/A3*, HER2* (negative controls). Reprinted with permission from: (A) Kawashima I, Hudson S, Tsai V et al. *Human Immunol* 1998; 59:1-14. ©American Society for Histocompatibility and Immunogenetics, 1998 Elsevier Science, Inc. (B) Kawashima I, Tsai V, Southwood S et al. *Cancer Res* 1999; 59:431-435. ©1999 Amer Assoc Cancer Res, Inc.

which bears some homology to the epidermal growth factor receptor.⁷³ Furthermore, the amplification and overexpression of this proto-oncogene on breast tumors has been associated with aggressive disease and poor prognosis. Other tumors, mainly adenocarcinomas of the ovary, colon and lung have also been reported to overexpress HER2. Since HER2 is selectively overexpressed in malignant cells and not in normal tissues, it has been considered as a possible antigen for CTL-mediated immunotherapy.^{23,75,76} Indeed, there are several reports demonstrating that some CTL from ovarian cancer patients are capable of recognizing peptides derived from the HER2 protein.^{23,25,77-79} Furthermore, there is also some evidence that helper T cells are capable of reacting with MHC class II peptides from HER2.^{76,80,81}

Using our T-cell epitope identification strategy we tested the capacity of MHC class I-binding peptides from HER2 to induce tumor-reactive CTL. Several HLA-A2 and a few HLA-A3 binding peptides from HER2 were analyzed for their ability to trigger primary CTL responses using DC as APC. The examples presented in Figure 1.4 demonstrate that CTL possessing a high level of cytotoxicity for HER2+ tumor cells were produced to both HLA-A2 and HLA-A3 MHC molecules.^{70,82}

Another TAA which is an ideal candidate for immunotherapy is CEA (carcinoembryonic antigen). CEA is a 180-kD glycoprotein that is extensively expressed on the vast majority of colorectal, gastric, and pancreatic carcinomas, it is also found in approximately 50% of breast cancers and on 70% of non-small-cell lung cancers.^{28,83-87} CEA is also present, but at usually at lower concentrations, in the normal colon epithelium and in some fetal tissues. Circulating CEA can be detected in the great majority of patients with CEA positive tumors and has been used to monitor responses to therapy and disease progression. Recently, CEA-reactive CTL


responses were reported virus expressing CEA.⁸¹ several novel CTL epitopes A2, -A3 and -A24.^{70,82} CEA-reactive CTL that activity towards CEA-exp

Enhancement of T-

The main consideration in developing immune-based vaccines representing "self antigens" is to ensure that the antigen is presented correctly, have the right MHC, and that the CTLs are correctly primed.⁸⁰ Another major consideration is the possibility of inducing an immune response which are predicted to be effective in demonstrating that peptides are predicted to be effective in stimulating an immune response was clearly shown that peptides from CTL epitopes from (YLEPGPVTA) and from significantly more potent and ELAGIGILT V (cor underlined), which include

In addition to the peptide from CEA can we wished to address the possibility of inducing CTLs by its MHC binding. Specific "canonical" A2.1 anchor analysis.⁵⁴ In order to (T) with the canonical binding to purified HLA and an "M" at position finding that the presence of binding capacity.^{55,92} approximately 40-fold peptide, CEA p24-33 is not capable, at least *in vitro* (data not shown) CTL induction. A CTL and gastric cancer cells

It has been reported that their MHC binding affinity of helper line specific for recognize a peptide and better than the natural



from HER2 can kill tumor cells. CTL HNGAYSL (panel A) or the HLA-specific CTL were used as effector cells. The appropriate HLA type pulsed with the appropriate peptide; △, SW403 cells (colon cancer) (negative controls). Reprinted with permission from Immunol 1998; 59:1-14. ©American Association of Cancer Research, Inc. (B) Kawashima I, Tsai V, Cancer Res, Inc.

ceptor.⁷³ Furthermore, the association of HER2 with adenocarcinomas of the breast. Since HER2 is selectively overexpressed in these tumors, it has been considered as a possible target for immunotherapy. There are several reports demonstrating the ability of recognizing peptides derived from some evidence that helper T cells recognize HER2.^{76,80,81}

The capacity of MHC class I molecules to bind a large number of different HLA-A2 and a few HLA-B27 peptides to trigger primary CTL responses. 1.4 demonstrate that CTLs can be produced to both HLA-A2

and B27. CEA (carcinoembryonic antigen) is expressed on the vast majority of breast tumors, approximately 50% of breast tumors also present, but at usually at low levels in fetal tissues. Circulating CEA-positive tumors and has been used recently, CEA-reactive CTL

responses were reported in cancer patients that were immunized with a recombinant vaccinia virus expressing CEA.⁸⁸ Following the same strategy as described above, we have identified several novel CTL epitopes restricted by commonly found MHC class I alleles such as HLA-A2, -A3 and -A24.^{70,82,89} The results presented in Figure 1.5 show that as with other TAA, CEA-reactive CTL that are induced with MHC-binding peptides exhibit significant lytic activity towards CEA-expressing tumor cells.

Enhancement of T-Cell Immunogenicity by Epitope Manipulation

The main consideration of using individual T-cell epitopes instead of whole proteins for developing immune-based therapy for cancer is that while vaccinations using intact proteins representing "self antigens" rarely induce CTL and T helper responses, peptides when administered correctly, have been shown to be capable of eliciting strong T-cell responses to tumor cells.⁸⁰ Another major advantage of identifying and utilizing tumor-associated T-cell epitopes is the possibility of increasing their biological activity by the substitution of critical residues which are predicted to enhance MHC binding and/or TCR reactivity. There are several reports demonstrating that peptide analogues of CTL and HTL epitopes can be 10-1000X more efficient in stimulating antigen-specific T cells than the natural peptide sequences. For example, it was clearly shown that peptide analogues corresponding to two well known HLA-A2-restricted CTL epitopes from the melanoma-associated antigens gp100/pmel-17, p280-288 (YLEPGPVTA) and from MART-1/Melan-A, p26-35 (EAAGIGILTV), were shown to be significantly more potent in triggering CTL responses in vitro.^{90,91} The analogs YLEPGPVTV and ELAIGIGILTV contained substitutions in the primary HLA-A2 binding anchors (shown underlined), which increased the binding of the peptide to this MHC molecule.

In addition to the above examples, our group has demonstrated that a non-immunogenic peptide from CEA can be engineered to elicit tumor-reactive CTL in vitro.⁷⁰ In these studies we wished to address whether a low/intermediate HLA-A2-binding peptide that was not capable of inducing CTL could be rendered immunogenic by modifications designed to enhance its MHC binding. Specifically, peptide CEA p24-33 (LMTFWNPPT) is missing one of the "canonical" A2.1 anchors (a V at the carboxyl terminal end), as defined by pool sequencing analysis.⁵⁴ In order to determine whether substituting the non-canonical C-terminal anchor (T) with the canonical residue, a peptide analog from CEA p24-33 was prepared and tested for binding to purified HLA-A2.1 molecules. This analog had a "V" at the carboxyl-terminal end and an "M" at position 2 (CEA p24-33/M2V9, sequence: LMTFWNPPTV), based on the finding that the presence of "M" in position 2 is frequently associated with optimal HLA-A2.1 binding capacity.^{55,92} The analog peptide bound to purified HLA-A2.1 molecules with an approximately 40-fold increase CEA p24-33/M2V9 (IC₅₀ 4.5 nM), as compared to the natural peptide, CEA p24-33 (IC₅₀ 178.6 nM). It was notable that although peptide CEA p24-33 was not capable, at least according to our experimental protocol, of triggering CTL responses in vitro (data not shown), the peptide analog CEA p24-33/M2V9 was immunogenic in terms of CTL induction. A CTL clone induced by the analog specifically recognized and killed colon and gastric cancer cells expressing the CEA and HLA-A2 antigens (Fig. 1.6).

It has been reported that MHC class II HTL epitopes can also be engineered to increase their MHC binding affinity and T-cell immunogenicity. For example, a melanoma-reactive T helper line specific for the tyrosinase antigen and restricted by HLA-DRB*0401 was shown to recognize a peptide analog with a substitution in one of the major MHC anchors, 10-100 X better than the natural peptide sequence.⁹³




Fig. 1.5. Cytotoxic T lymphocytes induced with HLA-binding peptides from CEA can kill tumor cells. CTL were induced with the HLA-A2-binding peptide, CEA p691-700 (IMIGVLGVV) (panel A) or the HLA-A3 binding peptide CEA p61-70 (HLFGYSWYK) (panel B). Peptide specific CTL were used as effector cells to test for the lysis of following target cell lines: O, EBV-LCL of the appropriate HLA type pulsed with CEA p691-700 (in A) or CEA p61-70 (in B); ●, EBV-LCL without peptide; Δ, SW403 cells (colon Ca, HLA-A2*/-A3*, CEA*); ◇, KATO-III cells (gastric Ca, HLA-A2*, CEA*); ▲, colon Ca cell line, HLA-A2*/-A3*, CEA* (negative controls). Reprinted with permission from: (A) Kawashima I, Hudson S, Tsai V et al. *Human Immunol* 1998; 59:1-14. ©American Society for Histocompatibility and Immunogenetics, 1998 Elsevier Science, Inc. (B) Kawashima I, Tsai V, Southwood S et al. *Cancer Res* 1999; 59:431-435. ©1999 Amer Assoc Cancer Res, Inc.

In summary, it is clear that T-cell epitope identification allows the unique advantage of designing more potent immunogens based on the modification of peptide sequences aimed towards increasing MHC binding affinity. Needless to say, this approach can be extremely useful when the targeted antigen represents a molecule which may be expressed in normal cells such as most TAA, where immune tolerance may need to be broken.

Conclusions

Therapeutic Approaches Using Defined T-Cell Epitopes

The ultimate goal of our research is to develop effective immunotherapies for both early (pre-metastatic) and advanced cancer patients utilizing the information derived from our T-cell epitope identification and re-engineering efforts. Because most patients suffering with advanced, metastatic disease are likely to be immunosuppressed due to their overall poor health status or as a result of chemo/radiation therapy, the logical approach to carry out anti-tumor immune intervention would be adoptive cellular therapy. TAA-specific CTL and HTL could be prepared *in vitro* as described above using CD8⁺ and CD4⁺ T-cells stimulated with autologous peptide-pulsed DC. It is foreseeable that in tissue culture (*ex vivo*) most of the immunosuppressive factors affecting the cancer patient can be eliminated. The *in vitro*-generated antigen-specific T-cells will then be expanded either by sequential stimulation with antigen or with mitogen (e.g., anti-CD3 antibody) as described by Riddell and Greenberg and later re-infused into the patients with or without the addition of systemic lymphokines (e.g., IL-2).




Fig. 1.6. Peptide anal sequence: LMTFWN target cell lines: O, E, Δ, SW403 (colon Ca, HLA-A2* assay. Lysis of ⁵¹Cr-labeled specific CTL clone w/ EBV-LCL pulsed with peptide (FLPSDYFPs I, Hudson S, Tsai V, and Immunog

Anti-tumor activity suitable for early (pre-immune system). Further adjuvant setting with immunization by the elimination of *in vivo* CTL activity at vaccination with syngeneic or presence of responses.⁹⁴⁻⁹⁶ How elimination of tumors. Furthermore, it has been shown that CTL epitopes can result in a favorable outcome for early (recently reported that vaccination in combination with anti-tumor immunization).

Another approach to T-cell epitopes are identifying multiple T-cell responses to most of whether these types of responses are capable of providing





Fig. 1.6. Peptide analogs can induce tumor-reactive CTL. Panel A: The CEA p24-33/M2V9 (analog, sequence: LMTFWNPPV) specific CTL clone was tested for its cytolytic activity against following target cell lines: ○, EBV-LCL cells pulsed with CEA p24-33/M2V9; ●, EBV-LCL without peptide; △, SW403 (colon Ca, HLA-A2*, CEA*); □, KATO-III (gastric Ca, HLA-A2*, CEA*); ▲, HT-29 (colon Ca, HLA-A2*, CEA*). Panel B: Antigen specificity demonstrated by cold target inhibition assay. Lysis of ^{51}Cr -labeled SW403 cells at an effector/target ratio of 2:1 by the CEA p24-33/M2V9 specific CTL clone was blocked at various Inhibitors / Target ratios by the following cold targets: ○, EBV-LCL pulsed with CEA p24-33/M2V9; ▲, EBV-LCL pulsed with irrelevant HLA-A2.1 binding peptide (FLPSDYFPSV); ●, EBV-LCL without peptide. Reprinted with permission from: Kawashima I, Hudson S, Tsai V et al. Human Immunol 1998; 59:1-14. ©American Society for Histocompatibility and Immunogenetics, 1998 Elsevier Science, Inc.

peptides from CEA can kill tumor cells. CTL 0 (IMIGVLGV) (panel A) or the HLA-peptide specific CTL were used as effector of the appropriate HLA type pulsed with out peptide; △, SW403 cells (colon Ca, CEA*); ▲, colon Ca cell line, HLA-A2* (A) Kawashima I, Hudson S, Tsai V et al. Compatibility and Immunogenetics, 1998 Cancer Res 1999; 59:431-435. ©1999

ion allows the unique advantage of ization of peptide sequences aimed y, this approach can be extremely ch may be expressed in normal cells e broken.

pitopes

ve immunotherapies for both early : information derived from our T- ause most patients suffering with pressed due to their overall poor logical approach to carry out anti- rapy. TAA-specific CTL and HTL and CD4⁺ T-cells stimulated with tissue culture (ex vivo) most of ient can be eliminated. The in d either by sequential stimulation scribed by Riddell and Greenberg addition of systemic lymphokines

Anti-tumor active immunotherapy (i.e., vaccination), on the other hand, will be more suitable for early (non-metastatic) disease, where patients are most likely to have an intact immune system. Furthermore, it becomes very attractive to utilize anti-tumor vaccines in the adjuvant setting with the aim of preventing tumor recurrences after primary conventional treatment by the elimination of micrometastases. Several potential approaches for inducing effective in vivo CTL and HTL responses to TAA can be contemplated. In many circumstances, vaccination with synthetic peptides representing the defined CTL and HTL epitopes in the absence or presence of adjuvants appears to be an easy and attractive way of inducing T-cell responses.⁹⁴⁻⁹⁶ However, although this mode of vaccination can effectively prevent the establishment of tumors (prophylaxis) it seldom has any benefit when used in the therapeutic mode. Furthermore, it has recently been reported that vaccination with certain peptides representing CTL epitopes can result in T-cell inactivation/deletion^{97,98} which would certainly be an undesirable outcome for the treatment of tumors. Notwithstanding the above concerns, it was recently reported that some melanoma patients exhibited tumor responses after receiving peptide vaccination in combination with GM-CSF or IL-2.¹¹⁻¹³ These results support further research in this area, where optimization of vaccination protocols could become an effective method of anti-tumor immunotherapy.

Another approach for inducing active immunity against TAA, especially when multiple T-cell epitopes are being considered, is the use of DNA-based vaccines. Plasmid vaccines containing multiple T-cell epitopes linked in tandem have been reported to induce strong T-cell responses to most of the components of the vaccine. Nevertheless, it remains to be determined whether these types of immunogens are capable of inducing sufficiently potent immune responses capable of providing benefit (extend disease-free survival) in cancer patients.

Currently, the most promising type of anti-tumor vaccine is the use of autologous peptide-pulsed DC. As mentioned previously, DC can relatively easily be prepared in tissue culture from monocytic precursors (CD14⁺ cells) that are incubated for approximately 1 week with GM-CSF and IL-4. Experiments in mouse models have shown that peptide-pulsed DC vaccination can effectively eliminate established tumors and extend disease-free survival.^{7,8} Also very encouraging is the recent observation that several melanoma patients vaccinated with autologous DC pulsed with melanoma-associated peptides demonstrated objective tumor responses.¹⁴ Thus, it appears that antigen-presenting DC are capable of overcoming potential immune tolerance and triggering immune responses to epitopes that are expressed in some normal tissues (melanocytes).

Finally, regardless of the vaccination strategy selected to induce anti-tumor CTL and HTL responses in individuals with established tumors, it becomes critical to carry out clinical studies with realistic endpoints. Unfortunately the evaluation of anti-tumor immunotherapy has been set to the standards of conventional cancer treatments such as chemo and radiation therapy where effectiveness is the reduction or elimination of measurable tumors. Many tumor immunologists, including myself and Dr. Martin Kast feel quite strongly that is naive to expect the disappearance of large tumor masses as a result of vaccination. More realistic and desirable endpoints such as 1) disease free survival, 2) overall survival with reasonable quality of life and 3) time to recurrence should be used to evaluate immunotherapy in cancer. Unfortunately, clinical studies designed to measure these endpoint require significant number of patients, a considerable amount of time (2-5 years minimal), a high amount of resources, and most importantly patience on the part of the clinical investigators and for-profit companies involved in the testing of potential new compounds.

References

1. Melief CJ. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. *Adv Cancer Res* 1992; 58:143-175.
2. Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. *Adv Immunol* 1991; 49:281-355.
3. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. *Immunol Today* 1997; :175-182.
4. Van Pel A, van der Bruggen P, Coulie PG et al. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. *Immunol Rev* 1995; 145:229-250.
5. Rosenberg SA, Packard BS, Aebersold PM et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. *N Engl J Med* 1988; 319:1676-1680.
6. Heslop HE, Ng CY, Li C et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. *Nat Med* 1996; 2:551-555.
7. Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with tumor peptides elicit protective and therapeutic anti-tumor immunity. *Nature Medicine* 1995; 1:1297-1303.
8. Mayordomo JI, Loftus DJ, Sakamoto H et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. *J Exp Med* 1996; 183:1357-1365.
9. Chen L, McGowan P, Ashe S et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. *J Exp Med* 1994; 179:523-532.
10. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8⁺ T cells by B7-transfected melanoma cells. *Science* 1993; 259:368-370.
11. Marchand M, Weynants P, Rankin E et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. *Int J Cancer* 1995; 63:883-885.
12. Jager E, Ringhoffer M, Dienes HP et al. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. *Int J Cancer* 1996; 67:54-62.
13. Rosenberg SA, Yan synthetic peptide v. 4:321-327.
14. Nestle FO, Alijagic lysate-pulsed dendr
15. Riddell SR, Greenl Rev Immunol 199
16. Riddell SR, Watan humans by the ad
17. Nabholz M, MacC
18. Berke G. The binc aspects. *Annu Rev*
19. Rammensee HG, Annu Rev Immun
20. Germain RN, Mat tation. *Annu Rev*
21. Urban JL, Schreib
22. Boon T, Cerottin Annu Rev Immun
23. Fisk B, Blevins Tl neu protooncogen 1995; 181:2109-2
24. Cheever MA, Che ras and chimeric
25. Yoshino I, Goede among human no
26. Nijman HW, Var cells. *Immunol L*
27. Keetch DW, And Dawson NA, Vogt
28. Shively J, Beatty Rev Oncol Hema
29. van der Bruggen cytolytic T lymph
30. Traversari C, van 1 is recognized o Exp Med 1992; :
31. van der Bruggen MAGE-1 nonape 2140.
32. van der Bruggen presented by HL/ 3. Eur J Immun
33. Gaugler B, Van antigen recogniz 179:921-930.
34. Brichard VG, H recognized on a 26:224-230.
35. Boon T, van de 1996; 183:725-7
36. Van den Eynde recognized by a 182:689-698.

is the use of autologous peptide be prepared in tissue culture or approximately 1 week with that peptide-pulsed DC vaccine disease-free survival.^{7,8} Also melanoma patients vaccinated with demonstrated objective tumor response and a high percentage of overcoming potential antigens that are expressed in some

immune anti-tumor CTL and HTL cells to carry out clinical studies for immunotherapy has been chemotherapeutic and radiation therapy tumors. Many tumor immunotherapies that are naive to expect the more realistic and desirable quality of life and response in cancer. Unfortunately, a significant number of patients, a lack of resources, and most importantly profit companies involved in

lymphocytes. *Adv Cancer Res*

operative in the recognition and

genes encoding cancer regression

tumor antigens recognized by

infiltrating lymphocytes and melanoma. A preliminary report.

immunity against Epstein-Barr virus infected lymphocytes. *Nat Med* 1996; 2:551-

dendritic cells pulsed with tumor antigens. *Lancet* 1995; 1:1297-

tumors with p53 wild-type and mutant. *Nat Med* 1995; 1:1365.

determines the effect of B7-1 on the proliferation of CD8+ T cells by B7-1.

responses in melanoma patients. *J Clin Invest* 1995; 95:883-885.

colony-stimulating factor- α and interleukin-2. *J Cancer* 1996; 67:54-62.

13. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. *Nat Med* 1998; 4:321-327.
14. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. *Nat Med* 1998; 4:328-332.
15. Riddell SR, Greenberg PD. Principles for adoptive T cell therapy of human viral diseases. *Annu Rev Immunol* 1995; 13:545-586.
16. Riddell SR, Watanabe KS, Goodrich JM et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. *Science* 1992; 257:238-241.
17. Nabholz M, MacDonald HR. Cytolytic T lymphocytes. *Annu Rev Immunol* 1983; 1:273-305.
18. Berke G. The binding and lysis of target cells by cytotoxic T lymphocytes: molecular and cellular aspects. *Annu Rev Immunol* 1994; 12:735-773.
19. Rammensee HG, Falk K, Rotzschke O. Peptides naturally presented by MHC class I molecules. *Annu Rev Immunol* 1993; 11:213-244.
20. Germain RN, Margulies DH. The biochemistry and cell biology of antigen processing and presentation. *Annu Rev Immunol* 1993; 11:403-450.
21. Urban JL, Schreiber H. Tumor antigens. *Annu Rev Immunol* 1992; 10:617-644.
22. Boon T, Cerottini JC, Van den Eynde B et al. Tumor antigens recognized by T lymphocytes. *Annu Rev Immunol* 1994; 12:337-365.
23. Fisk B, Blevins TL, Wharton JT et al. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. *J Exp Med* 1995; 181:2109-2117.
24. Cheever MA, Chen W, Disis ML et al. T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl. *Ann N Y Acad Sci* 1993; 690:101-112.
25. Yoshino I, Goedegebuure PS, Peoples GE et al. HER2/neu-derived peptides are shared antigens among human non-small lung cancer and ovarian cancer. *Cancer Res* 1994; 54:3387-3390.
26. Nijman HW, Van der Burg SH, Vierboom MP et al. p53, a potential target for tumor-directed T cells. *Immunol Letters* 1994; 40:171-178.
27. Keetch DW, Andriole GL. The use of tumor markers in prostate cancer. In *Prostate Cancer* (eds Dawson NA, Vogelzang NJ) 95-112 (Wiley-Liss, Inc., New York, 1994).
28. Shively J, Beatty J. CEA-related antigens: Molecular biological and clinical significance. *CRC Crit Rev Oncol Hematol* 1985; 2:355-399.
29. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. *Science* 1991; 254:1643-1647.
30. Traversari C, van der Bruggen P, Luescher IF et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. *J Exp Med* 1992; 176:1453-1457.
31. van der Bruggen P, Szikora JP, Boel P et al. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. *Eur J Immunol* 1994; 24:2134-2140.
32. van der Bruggen P, Bastin J, Gajewski T et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. *Eur J Immunol* 1994; 24:3038-3043.
33. Gaugler B, Van den Eynde B, van der Bruggen P et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. *J Exp Med* 1994; 179:921-930.
34. Brichard VG, Herman J, Van Pel A et al. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes. *Eur J Immunol* 1996; 26:224-230.
35. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. *J Exp Med* 1996; 183:725-729.
36. Van den Eynde B, Peeters O, De Backer O et al. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. *J Exp Med* 1995; 182:689-698.

37. Boel P, Wildmann C, Sensi ML et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. *Immunity* 1995; 2:167-175.
38. Wolfel T, Van Pel A, Brichard V et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. *Eur J Immunol* 1994; 24:759-764.
39. Coulic PG, Brichard V, Van Pel A et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. *J Exp Med* 1994; 180:35-42.
40. Kawakami Y, Eliyahu S, Delgado CH et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. *Proc Natl Acad Sci (USA)* 1994; 91:3515-3519.
41. Kawakami Y, Eliyahu S, Sakaguchi K et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. *J Exp Med* 1994; 180:347-352.
42. Kawakami Y, Eliyahu S, Delgado CH et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. *Proc Natl Acad Sci (USA)* 1994; 91:6458-6462.
43. Robbins PF, el-Gamil M, Kawakami Y et al. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. *Cancer Res* 1994; 54:3124-3126.
44. Kang X, Kawakami Y, el-Gamil M et al. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. *J Immunol* 1995; 155:1343-1348.
45. Kawakami Y, Eliyahu S, Jennings C et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating lymphocytes associated with in vivo tumor regression. *J Immunol* 1995; 154:3961-3968.
46. Houghton AN. Cancer antigens: immune recognition to self and altered self. *J Exp Med* 1994; 180:1-4.
47. Castelli C, Storkus WJ, Maeurer MJ et al. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. *J Exp Med* 1995; 181:363-368.
48. Cox AL, Skipper J, Chen Y et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. *Science* 1994; 264:716-719.
49. Skipper JCA, Hendrickson RC, Gulden PH et al. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. *J Exp Med* 1996; 183:527-534.
50. Celis E, Sette A, Grey HM. Epitope selection and development of peptide based vaccines to treat cancer. *Sem Cancer Biol* 1995; 6:329-336.
51. Celis E, Fikes J, Wentworth P et al. Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles. *Molec Immunol* 1994; 31:1423-1430.
52. Celis E, Tsai V, Crimi C et al. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. *Proc Natl Acad Sci (USA)* 1994; 91:2105-2109.
53. Appella E, Loftus DJ, Sakaguchi K et al. Synthetic antigenic peptides as a new strategy for immunotherapy of cancer. *Biomedical Peptides, Proteins and Nucleic Acids* 1995; 1:177-184.
54. Rammensee H-G, Friede T, Stevanovic S. MHC ligands and peptide motifs: first listing. *Immunogenet* 1995; 41:178-228.
55. Ruppert J, Sidney J, Celis E et al. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. *Cell* 1993; 74:929-937.
56. Kubo RT, Sette A, Grey HM et al. Definition of specific peptide motifs for four major HLA-A alleles. *J Immunol* 1994; 152:3913-3924.
57. Kondo A, Sidney J, Southwood S et al. Two distinct HLA-A*0101-specific submotifs illustrate alternative peptide binding modes. *Immunogenet* 1997; 45:249-258.
58. Southwood S, Sidney J, Kondo A et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. *J Immunol* 1998; 160:3363-3373.
59. Geluk A, van Meijgaarden KE, Southwood S et al. HLA-DR3 molecules can bind peptides carrying two alternative specific submotifs. *J Immunol* 1994; 152:5742-5748.
60. Sette A, Sidney J, del Guercio MF et al. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. *Molec Immunol* 1994; 31:813-822.

61. Tsai V, Kawakami Y. Cytotoxic T lymphocyte recognition of melanoma antigens. *Rev Immunol* 1995; 32:603-612.
62. Sercarz EE, Lantini A. Antigen presentation by MHC class II molecules. *Annu Rev Immunol* 1995; 13:1-42.
63. Wentworth P. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. *J Exp Med* 1994; 180:35-42.
64. Romani N, Cappelletti M, Piccoli M et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. *J Exp Med* 1994; 180:347-352.
65. Sallusto F, Lanzetta C, Mackay LK et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. *Proc Natl Acad Sci (USA)* 1994; 91:6458-6462.
66. Weynants P, Brochez V, De Maesseneire J et al. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. *Cancer Res* 1994; 54:3124-3126.
67. De Plaen E, Brochez V, De Maesseneire J et al. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. *J Immunol* 1995; 155:1343-1348.
68. Russo V, Trinchieri P, Santoro SA et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating lymphocytes associated with in vivo tumor regression. *J Immunol* 1995; 154:3961-3968.
69. Fleischauer I, Krawinkel U, Krawinkel U et al. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. *J Exp Med* 1995; 181:363-368.
70. Cox AL, Skipper J, Chen Y et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. *Science* 1994; 264:716-719.
71. Skipper JCA, Hendrickson RC, Gulden PH et al. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. *J Exp Med* 1996; 183:527-534.
72. Celis E, Sette A, Grey HM. Epitope selection and development of peptide based vaccines to treat cancer. *Sem Cancer Biol* 1995; 6:329-336.
73. Celis E, Fikes J, Wentworth P et al. Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles. *Molec Immunol* 1994; 31:1423-1430.
74. Celis E, Tsai V, Crimi C et al. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. *Proc Natl Acad Sci (USA)* 1994; 91:2105-2109.
75. Appella E, Loftus DJ, Sakaguchi K et al. Synthetic antigenic peptides as a new strategy for immunotherapy of cancer. *Biomedical Peptides, Proteins and Nucleic Acids* 1995; 1:177-184.
76. Rammensee H-G, Friede T, Stevanovic S. MHC ligands and peptide motifs: first listing. *Immunogenet* 1995; 41:178-228.
77. Ruppert J, Sidney J, Celis E et al. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. *Cell* 1993; 74:929-937.
78. Kubo RT, Sette A, Grey HM et al. Definition of specific peptide motifs for four major HLA-A alleles. *J Immunol* 1994; 152:3913-3924.
79. Kondo A, Sidney J, Southwood S et al. Two distinct HLA-A*0101-specific submotifs illustrate alternative peptide binding modes. *Immunogenet* 1997; 45:249-258.
80. Southwood S, Sidney J, Kondo A et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. *J Immunol* 1998; 160:3363-3373.
81. Geluk A, van Meijgaarden KE, Southwood S et al. HLA-DR3 molecules can bind peptides carrying two alternative specific submotifs. *J Immunol* 1994; 152:5742-5748.
82. Sette A, Sidney J, del Guercio MF et al. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. *Molec Immunol* 1994; 31:813-822.
83. Tsai V, Kawakami Y. Cytotoxic T lymphocyte recognition of melanoma antigens. *Rev Immunol* 1995; 32:603-612.
84. Sercarz EE, Lantini A. Antigen presentation by MHC class II molecules. *Annu Rev Immunol* 1995; 13:1-42.

61. Tsai V, Kawashima I, Keogh E et al. In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells. *Crit Rev Immunol* 1998; 18:65-75.
62. Sercarz EE, Lehmann PV, Ametani A et al. Dominance and crypticity of T cell antigenic determinants. *Annu Rev Immunol* 1993; 11:729-766.
63. Wentworth PA, Celis E, Crimi C et al. In vitro induction of primary, antigen-specific CTL from human peripheral blood mononuclear cells stimulated with synthetic peptides. *Molec Immunol* 1995; 32:603-612.
64. Romani N, Gruner S, Brang D et al. Proliferating dendritic cell progenitors in human blood. *J Exp Med* 1994; 180:83-93.
65. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α . *J Exp Med* 1994; 179:1109-1118.
66. Weynants P, Lethe B, Brasseur F et al. Expression of MAGE genes by non-small-cell lung carcinomas. *Int J Cancer* 1994; 56:826-829.
67. De Plaen E, Arden K, Traversari C et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. *Immunogenet* 1994; 40:360-369.
68. Russo V, Traversari C, Verrecchia A et al. Expression of the MAGE gene family in primary and metastatic human breast cancer. Implications for tumor antigen-specific immunotherapy. *Int J Cancer* 1995; 64:216-221.
69. Fleischhauer K, Fruci D, Van Endert P et al. Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3. *Int J Cancer* 1996; 68:622-628.
70. Kawashima I, Hudson S, Tsai V et al. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. *Human Immunol* 1998; 59:1-14.
71. Dong RP, Kimura A, Okubo R et al. HLA-A and DPB1 loci confer susceptibility to Graves' disease. *Human Immunol* 1992; 35:165-172.
72. Tanaka F, Fujie T, Tahara K et al. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. *Cancer Res* 1997; 57:4465-4468.
73. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. *Science* 1989; 244:707-712.
74. Yokota J, Yamamoto T, Toyoshima K et al. Amplification of the c-erbB-2 oncogene in human adenocarcinomas in vivo. *Lancet* 1986; 1:765-767.
75. Ioannides CG, Fisk B, Fan D et al. Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. *Cell Immunol* 1993; 151:225-234.
76. Cheever MA, Disis ML, Bernhard H et al. Immunity to oncogenic proteins. *Immunol Rev* 1995; 145:33-59.
77. Lustgarten J, Theobald M, Labadie C et al. Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD8. *Human Immunol* 1997; 52:109-118.
78. Disis ML, Smith JW, Murphy AE et al. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. *Cancer Res* 1994; 54:1071-1076.
79. Peoples GE, Goedegebuure PS, Smith R et al. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. *Proc Natl Acad Sci U S A* 1995; 92:432-436.
80. Disis ML, Gralow JR, Bernhard H et al. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, an oncogenic self-protein. *J Immunol* 1996; 156:3151-3158.
81. Disis ML, Cheever MA. HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. *Adv Cancer Res* 1997; 71:343-371.
82. Kawashima I, Tsai V, Southwood S et al. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. *Cancer Res* 1999; 59:431-435.
83. Vincent RG, Chu TM. Carcinoembryonic antigen in patients with carcinoma of the lung. *J Thorac Cardiovasc Surg* 1978; 66:320-328.
84. Thompson J, Grunert F, Zimmerman W. CEA gene family: Molecular biology and clinical perspectives. *J Clin Lab Anal* 1991; 5:344-366.

encoding an antigen recognized on
1995; 2:167-175.

epitopes recognized on HLA-A2 mela-
1994; 24:759-764.

g for a differentiation antigen recog-
nized on HLA-A2 mela-
1994; 180:35-42
coding for a shared human mela-
to tumor. *Proc Natl Acad Sci (USA)*

he immunodominant peptides of the
ty of HLA-A2-restricted tumor infil-

a human melanoma antigen recog-
no tumor rejection. *Proc Natl Acad*

tyrosinase by tumor-infiltrating lym-
1994; 54:3124-3126.

tyrosinase epitope recognized by HLA-
1995; 155:1343-1348.

multiple epitopes in the human mela-
ted with in vivo tumor regression. *J*

and altered self. *J Exp Med* 1994;

c identification of a naturally pro-
hocytes. *J Exp Med* 1995; 181:363-

cognized by five melanoma-specific

A2-restricted tyrosinase antigen on
suggests a novel pathway for pro-

: of peptide based vaccines to treat

CTL epitopes of tumor-associated
1994; 31:1423-1430.

cytotoxic T lymphocytes in normal hu-
1994; 181:363-

oxides as a new strategy for immu-
1995; 1:177-184.

and peptide motifs: first listing.

anchor residues in peptide binding

peptide motifs for four major HLA-A-

0101-specific submotifs illustrate
1995; 1:177-184.

IR types share largely overlapping

molecules can bind peptides carry-
1995; 1:177-184.

the most frequent HLA-A class I
1994; 31:813-822.

85. Sikorska H, Shuster J, Gold P. Clinical applications of carcinoembryonic antigen. *Cancer Detect Prev* 1988; 12:321-355.
86. Muraro R, Wunderlich D, Thor A. Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues. *Cancer Res* 1985; 45:57.
87. Steward AM, Nixon D, Zamcheck N et al. Carcinoembryonic antigen in breast cancer patients: Serum levels and disease progress. *Cancer* 1974; 33:1246-1252.
88. Tsang KY, Zaremba S, Nieroda CA et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. *J Natl Cancer Inst* 1995; 87:982-990.
89. Nukaya I, Yasumoto M, Iwasaki T et al. Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. *Int J Cancer* 1999; 80:92-97.
90. Parkhurst MR, Salgaller ML, Southwood S et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. *J Immunol* 1996; 157:2539-2548.
91. Valmori D, Fonteneau JF, Lizana CM et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. *J Immunol* 1998; 160:1750-1758.
92. del Guercio MF, Sidney J, Hermanson G et al. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. *J Immunol* 1995; 154:685-693.
93. Topalian SL, Gonzales MI, Parhurst M et al. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. *J Exp Med* 1996; 183:1965-1971.
94. Feltkamp MC, Smits HL, Vierboom MP et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. *Eur J Immunol* 1993; 23:2242-2249.
95. Melief CJ. Prospects of T-cell immunotherapy for cancer by peptide vaccination. *Sem Hematol* 1993; 30:32-33.
96. Melief CJ, Offringa R, Toes RE et al. Peptide-based cancer vaccines. *Curr Opin Immunol* 1996; 8:651-657.
97. Toes RE, van der Voort EI, Schoenberger SP et al. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. *J Immunol* 1998; 160:4449-4456.
98. Toes RE, Offringa R, Blom RJ et al. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. *Proc Natl Acad Sci U S A* 1996; 93:7855-7860. *in vitro*

CHAPTER 2

Mutant Oncogene Produced by Chromosomes for Cancer Vaccines

V. Ellen Maher, B. S. Michael J. Kelley, M. Leon van den Broek and Jay A. Berzofsky

Introduction

Active immunotherapy is strong evidence and levamisole, have been used as therapies: system include tumors withdrawal of that there examples of the efficacy a clinical response in patients has grown with our unc schemes have been carried these trials have been checked the specificity of tumor seen, is to use our increased Molecular changes which mutant proteins and checked a unique immunologic of overexpressed and mediated by chromosomal mutations tional advantage that cell, so that escape malignant phenotype.

Our understanding two decades. However, eliminate the cancer cell key element in the development